according to Lemon Tree Hotels shares rise 4% on likely increase in occupancy, addition of roomsMoneycontrol NewsLemon Tree Hotels share price gained more than 4 percent intraday Tuesday as investors cheer company's future plans. Related NewsThe company has been opening new hotels in deep-demand markets, he said, adding it is currently operating 5,000 rooms in 50 hotels and will be adding 3,200 rooms in next 3 years. Lemon Tree Hotels' debt will peak at Rs 1,300 crore in FY19, from current Rs 1,000 crore, he said. The stock has been rallied more than 35 percent from its issue price of Rs 56 per share. At 13:52 hours IST, the stock price was quoting at Rs 75, up Rs 2.15, or 2.95 percent on the BSE.
as declared in
Tesla shares rise as carmaker plans massive China factory
Telsa is planning to build a large new plant in China, the company confirmed on Tuesday. "Today, we have signed a Cooperative Agreement for Tesla to start building Gigafactory 3, a new electric vehicle manufacturing facility in Shanghai," a Tesla spokesperson said in an emailed statement Tuesday. From there, it will take roughly two years until we start producing vehicles and then another two to three years before the factory is fully ramped up." The company said the factory will eventually be able to produce 500,000 vehicles per year for Chinese customers. "Tesla is deeply committed to the Chinese market, and we look forward to building even more cars for our customers here," the spokesperson added.
as declared in
Market PulsePfizer shares rise after President Trump attacks its drug price hikesPresident Donald Trump criticized pharmaceutical giant Pfizer Inc. PFE+0.73% in a Monday tweet for recently increasing the prices of many of its prescription drugs. Pfizer shares rose 0.5% in heavy early afternoon trade. The presidential tweet follows a Financial Times report that Pfizer raised list prices for 100 products in early July, weeks after Trump promised large price reductions, and marking the second such increase this year for Pfizer. Pfizer told the Financial Times that the increases, which were made on the drugs' so-called "list prices," did not reflect net price increases, estimated to be in the low single digits. Drug companies tend to increase the prices of their drugs early in the year and then again in the summer, and Pfizer was one of several to do so this month.